Brazikumab ( AMG139, previously known as MEDI2070 ) is a key therapeutic drug targeting the IL-17F cytokine. New trial data from the phase 3 IMMU-NYMPH3 study evaluating its efficacy in patients with https://amg139821140.wikicorrespondence.com/user